Last update 16 May 2025

ERX-315

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ERX315
Target
LIPA
Action
modulators
Mechanism
LIPA modulators(lipase A, lysosomal acid type modulators)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [2]
Active Indication
Advanced Malignant Solid NeoplasmLiver metastasesMetastatic breast cancer+ [4]
Inactive Indication-
Originator Organization
EtiraRx LLCEtiraRx LLC
Active Organization
University of Texas Health Science Center At San AntonioUniversity of Texas Health Science Center At San AntonioThe University of Texas at DallasThe University of Texas at DallasTexas State UniversityTexas State University
+ [1]
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with ERX-315
NCT06533332
/ RecruitingPhase 1
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors
100 Clinical Results associated with ERX-315
Login to view more data
100 Translational Medicine associated with ERX-315
Login to view more data
100 Patents (Medical) associated with ERX-315
Login to view more data
100 Deals associated with ERX-315
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
Australia
-14 Oct 2024
Liver metastasesPhase 1
Australia
-14 Oct 2024
Metastatic breast cancerPhase 1
Australia
-14 Oct 2024
Metastatic endometrial cancerPhase 1
Australia
-14 Oct 2024
Metastatic Pancreatic CancerPhase 1
Australia
-14 Oct 2024
Ovarian CancerPhase 1
Australia
-14 Oct 2024
Hepatocellular CarcinomaPreclinical
United States
University of Texas Health Science Center At San AntonioUniversity of Texas Health Science Center At San Antonio
28 Apr 2025
Hepatocellular CarcinomaPreclinical
United States
The University of Texas at DallasThe University of Texas at Dallas
28 Apr 2025
Hepatocellular CarcinomaPreclinical
United States
Texas State UniversityTexas State University
28 Apr 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free